Probing Mutant KRAS, STK11, KEAP1 in NSCLC

According to an exploratory analysis of data from the POSEIDON trial, patients with non-small cell lung cancer and KRAS, STK11, or KEAP1 mutations fared better on the three-drug combination of tremelimumab and durvalumab plus chemotherapy compared with chemotherapy alone. However, small sample sizes precluded any definitive interpretation of the findings.